Welcome to our dedicated page for LakeShore Biopharma news (Ticker: LSB), a resource for investors and traders seeking the latest updates and insights on LakeShore Biopharma stock.
LakeShore Biopharma Co., Ltd. reports developments as a global biopharmaceutical company focused on vaccines and therapeutic biologics for infectious diseases and cancer. Company updates center on the PIKA® immunomodulating technology platform, the YSJA™ rabies vaccine, and preventive or therapeutic biologics targeting rabies, hepatitis B, influenza and other viral infections.
Recurring news also covers operating and financial results, clinical and regulatory disclosures, material agreements, shareholder voting matters, capital-structure updates, and governance actions. Corporate-status coverage includes the suspension of the company’s ordinary shares and warrants from Nasdaq and their OTC market trading under LSBCF and LSBWF.
LakeShore Biopharma (Nasdaq: LSB) will hold an Extraordinary General Meeting (EGM) on July 25, 2024, following a shareholders' requisition. The requisition, dated June 14, 2024, was issued by shareholders holding at least 10% of the voting shares, including Yi Zhang and several investment firms. The EGM will address key issues such as the reasons for recent director resignations, the establishment of new subsidiaries, and the potential impact of ongoing arbitration proceedings. The meeting will be held virtually via Zoom, and shareholders of record on July 15, 2024, are entitled to vote. Detailed information is available on the company's website and will be included in the Form 6-K filed with the SEC.